A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229

NCT ID: NCT07285603

Last Updated: 2025-12-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-21
• Study Completion Date: 2025-06-18

Brief Summary

This is a Phase I, single-center, randomized, single-blind, placebo-controlled study in healthy subjects assessing the safety, tolerability and pharmacokinetic profile of three different dose levels of M6229 when administered continuously for 120 hours.

Detailed Description

Three dose levels of M6229 will be assessed in sequential study cohorts. Each cohort will consist of up to 3 male and 3 female subjects (2 male and 2 female subjects on M6229, 1 male and 1 female subject on placebo). Following a screening period of up to 28 days during which eligibility will be assessed, subjects will be randomized to M6229 or placebo and start a 120-hour continuous infusion on Day 1. Subjects will undergo safety assessments (incl. laboratory assessments) and pharmacokinetic sampling following a predefined schedule from Day 1 until Day 9. Subjects will be discharged on Day 9. The clinical study will be completed with an end-of-study visit, which will take place between 5 to 9 days after the last treatment-defined assessment.

Conditions

Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

M6229

A low-anticoagulant heparin in low, mid, and high dose. IV administration.

Group Type: EXPERIMENTAL

M6229

Intervention Type: DRUG

Continuous 120-hour intravenous infusion of M6229

Placebo

Saline solution; IV administration

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Continuous 120-hour intravenous infusion of placebo (saline)

Interventions

M6229

Continuous 120-hour intravenous infusion of M6229

Intervention Type: DRUG

Placebo

Continuous 120-hour intravenous infusion of placebo (saline)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Provision of written informed consent
• Male or female, aged 18 - 55 years at time of informed consent
• BMI between 18.0 - 30.0 kg/m2
• Normal vital signs (resting pulse rate and resting blood pressure)
• Normal ECG parameters (PR, QRS, QTc)
• Normal coagulation parameters (aPTT, PTT/INR and thrombin time)
• Female subjects must have a negative serum pregnancy test
• Willing and able to adhere to contraceptive requirements

Exclusion Criteria

• History of clinically significant medical illness
• Laboratory abnormalities
• Major surgery or trauma in previous 6 months
• Positive test for HIV, HBsAg, or HCV
• History of heart arrhythmias, tachycardia at rest, or history of risk factors for Torsade de Pointes syndrome
• Clinically relevant allergy or drug hypersensitivity (incl. heparin)
• Smokes daily more than 5 cigarettes or equivalent
• History of postural disorders
• Lack of adequate venous access
• Current or ongoing history of urinary retention
• Use of prescription or nonprescription medication within 7 days prior to Day 1
• Received an investigational drug or medical device recently, or >3 investigational agents in last 12 months, or currently enrolled in an investigational study
• Donated blood or substantial blood loss within 60 days prior to Day 1
• Any condition, preplanned surgery or procedure that would interfere with the study conduct and/or with the subject's best interest
• Subject is vulnerable
• Subject is an employee of the investigator, clinical site, or Sponsor

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Matisse Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Charité Research

Berlin, , Germany

Countries

Germany

References

Iten PX, Meier M. Beta-hydroxybutyric acid--an indicator for an alcoholic ketoacidosis as cause of death in deceased alcohol abusers. J Forensic Sci. 2000 May;45(3):624-32.

Reference Type: BACKGROUND

PMID: 10855969 (View on PubMed)

Zimmer KP, Lentze MJ, Nutzenadel W, Rodeck B. On the situation of pediatric gastroenterology in a so-called developed country. J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):241-2. doi: 10.1097/00005176-200209000-00001. No abstract available.

Reference Type: BACKGROUND

PMID: 12360993 (View on PubMed)

Related Links

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-512022-28-01

Related Info

Other Identifiers

M6229-C002

Identifier Type: -

Identifier Source: org_study_id